Bevacizumab Multimodal Regimen ‘Feasible’ for Rectal Cancer

Bevacizumab may boost pathological response to pre- and postoperative chemotherapy for T3 rectal cancer...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.